CVS Health to remove AbbVie rheumatoid arthritis drug Humira from some drug reimbursement lists in April Ruchika Sharma4 Jan 2024 12:30 PM ISTA CVS spokesperson said the company expects most of its customers to transition their coverage to biosimilars of Humira, known chemically as...
Sandoz gets European Commission nod for Hyrimoz high-concentration formulation Ruchika Sharma4 April 2023 2:00 PM ISTAdalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
Sandoz Supplemental Biologics License application accepted by US FDA for biosimilar Hyrimoz high concentration formulation Ruchika Sharma24 July 2022 10:00 AM ISTAdalimumab is a human immunoglobulin G1 (IgG(1)) monoclonal antibody targeting tumor necrosis factor alpha (TNF-a).
Novartis division Sandoz application for proposed biosimilar Hyrimoz's high concentration formulation accepted by EMA Ruchika Sharma19 Jun 2022 11:30 AM ISTUpon approval, the Hyrimoz (100 mg/mL) citrate-free HCF would offer reduced injection volume and potentially decrease the number of injections...
Sandoz launches biosimilar Hyrimoz in Canada Ruchika Sharma18 Feb 2021 12:33 PM ISTHyrimoz is a fully human tumor necrosis factor (TNF) blocker which helps to reduce inflammation.
